Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 5
Submit an article Journal homepage
287
Views
2
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score

Eriko SatoDepartment of Medicine, Division of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan;
,
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Correspondence[email protected]
,
Michihide TokuhiraDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan;
,
Tomoiku TakakuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan;
,
Maho IshikawaDepartment of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan;
,
Tomonori NakazatoDepartment of Hematology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan;
,
Kei-Ji SugimotoDepartment of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan;
,
Hiroyuki FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan;
,
Isao FujiokaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan;
,
Norio AsouDepartment of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan;
,
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan;
,
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan;
,
Yoshihiro HattaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
&
Tatsuya KawaguchiDepartment of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan
 show all
Pages 1105-1112 | Received 27 Mar 2017, Accepted 01 Aug 2017, Published online: 25 Aug 2017

References

  • Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
  • Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585–590.
  • de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–3363.
  • Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869–874.
  • Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–1145.
  • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259.
  • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–2270.
  • Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
  • Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353–1360.
  • Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686–692.
  • Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27:2016–2022.
  • Iriyama N, Hatta Y, Kobayashi S, et al. The European treatment and outcome study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int J Hematol. 2014;100:379–385.
  • Tao Z, Liu B, Zhao Y, et al. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib. Leuk Res. 2014;38:1030–1035.
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–2340.
  • Iriyama N, Fujisawa S, Yoshida C, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90:282–287.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
  • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
  • Kanda Y. Investigation of the freely available easy-to-use software “EZR for medical statistics”. Bone Marrow Transplant. 2013;48:452–458.
  • Breccia M, Finsinger P, Loglosci G, et al. The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line. Leuk Res. 2012;36:e209–e210.
  • Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119:4524–4526.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.